Astrazeneca Plc [Swe (AZNDF) 72.1540 $AZNDF
Teva to pay $1.2 billion in drug-delay settlement
By MATTHEW PERRONE - AP - Thu May 28, 12:22PM CDT
WASHINGTON (AP) — Federal regulators announced Thursday that Teva Pharmaceuticals Industries will pay $1.2 billion to settle charges that one of its subsidiaries illegally blocked the launch of low-cost generic versions of the blockbuster sleeping pill Provigil.
AZN: 66.45 (+1.90)
Amgen ends work on experimental psoriasis drug
AP - Fri May 22, 4:27PM CDT
NEW YORK (AP) — Drugmakers Amgen and AstraZeneca said Friday that some patients who took an experimental psoriasis drug experienced suicidal thoughts or behavior, and Amgen said it is ending development of the drug.
AZN: 66.45 (+1.90), AMGN: 154.10 (+2.79)
Xerox and Amazon are big market movers
AP - Fri Apr 24, 3:35PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
AMZN: 443.51 (+9.12), DDD: 16.82 (+0.11), XRX: 10.38 (+0.14), CMCSK: 62.95 (+1.16), UAL: 55.51 (+2.25), SBUX: 54.57 (+0.52), SCHL: 44.45 (+0.52), ARRS: 30.85 (+0.55), AZN: 66.45 (+1.90), PHM: 20.69 (+0.37), GM: 31.40 (+0.39), DPZ: 115.92 (+2.23), TWC: 183.50 (+2.15), HMHC: 25.78 (+0.54), CMCSA: 63.19 (+1.18), UNP: 97.82 (+1.57)
AstraZeneca profit falls as patent expires on heartburn drug
AP - Fri Apr 24, 3:56AM CDT
LONDON (AP) — Anglo-Swedish drug-maker AstraZeneca PLC reported a 7 percent fall in net profit for the first quarter of 2015, as cheaper copies of one of its best-sellers ate into sales.
AZN: 66.45 (+1.90)
Pfizer net down on lower sales, higher research, legal costs
By LINDA A. JOHNSON - AP - Tue Jan 27, 12:43PM CST
Pfizer Inc.'s fourth-quarter profit fell by half as worsening generic competition and unfavorable currency rates reduced sales, and higher research and legal costs also reduced the bottom line.
AZN: 66.45 (+1.90), PFE: 34.36 (+0.50)
Pension charge, lower sales slash Bristol-Myers' Q4 profit
By LINDA A. JOHNSON - AP - Tue Jan 27, 6:58AM CST
NEW YORK (AP) — Bristol-Myers Squibb Co. barely broke even in the fourth quarter, due to a whopping pension charge and slightly lower prescription drug sales, but the drugmaker easily beat Wall Street's muted profit expectations.
AZN: 66.45 (+1.90), BMY: 69.27 (+1.38)
One dose, then surgery: A new way to test brain tumor drugs
By MARILYNN MARCHIONE - AP - Fri Jan 23, 12:57AM CST
Lori Simons took the bright orange pill at 3 a.m. Eight hours later, doctors sliced into her brain, looking for signs that the drug was working.
AZN: 66.45 (+1.90)
AstraZeneca cancer drug, companion test approved
By LINDA A. JOHNSON - AP - Fri Dec 19, 1:39PM CST
TRENTON, N.J. (AP) — U.S. regulators on Friday granted accelerated approval to the first in a new class of targeted drugs for ovarian cancer, Lynparza from British drugmaker AstraZeneca PLC.
MYGN: 34.32 (+0.82), AZN: 66.45 (+1.90)
FDA OKs new AstraZeneca diabetes combo pill
AP - Thu Oct 30, 10:05AM CDT
WILMINGTON, Del. (AP) — AstraZeneca said Thursday it received U.S. approval for a new diabetes medication that combines its drug Farxiga with an older drug used to control blood sugar levels.
AZN: 66.45 (+1.90)
Nektar says FDA clears constipation drug Movantik
AP - Tue Sep 16, 1:02PM CDT
NEW YORK (AP) — Nektar Therapeutics said Tuesday that U.S. regulators approved its drug Movantik, a once-per-day treatment for constipation caused by opioid painkillers.
AZN: 66.45 (+1.90)
Merck 2Q profit more than doubles
By LINDA A. JOHNSON - AP - Tue Jul 29, 10:45AM CDT
A big one-time gain and a tax benefit helped drugmaker Merck & Co. more than double second-quarter profit, improve its profit forecast and top analysts' expectations.
SHPG: 250.34 (+7.35), AZN: 66.45 (+1.90), MRK: 57.95 (+0.57), ABBV: 69.23 (+1.26)
Bristol 2Q net drops on lower drug sales, charges
AP - Thu Jul 24, 9:53AM CDT
NEW YORK (AP) — Bristol-Myers Squibb Co.'s exit from the diabetes business, plus higher taxes and research spending, combined to slash the drugmaker's second-quarter profit by 38 percent, but the company handily beat Wall Street's muted profit expectations.
PFE: 34.36 (+0.50), AZN: 66.45 (+1.90), BMY: 69.27 (+1.38)
Teva to pay $1.2 billion in drug-delay settlement
By MATTHEW PERRONE - AP - Thu May 28, 12:22PM CDT
WASHINGTON (AP) — Federal regulators announced Thursday that Teva Pharmaceuticals Industries will pay $1.2 billion to settle charges that one of its subsidiaries illegally blocked the launch of low-cost generic versions of the blockbuster sleeping pill Provigil.
AZN: 66.45 (+1.90)
Amgen ends work on experimental psoriasis drug
AP - Fri May 22, 4:27PM CDT
NEW YORK (AP) — Drugmakers Amgen and AstraZeneca said Friday that some patients who took an experimental psoriasis drug experienced suicidal thoughts or behavior, and Amgen said it is ending development of the drug.
AZN: 66.45 (+1.90), AMGN: 154.10 (+2.79)
Xerox and Amazon are big market movers
AP - Fri Apr 24, 3:35PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
AMZN: 443.51 (+9.12), DDD: 16.82 (+0.11), XRX: 10.38 (+0.14), CMCSK: 62.95 (+1.16), UAL: 55.51 (+2.25), SBUX: 54.57 (+0.52), SCHL: 44.45 (+0.52), ARRS: 30.85 (+0.55), AZN: 66.45 (+1.90), PHM: 20.69 (+0.37), GM: 31.40 (+0.39), DPZ: 115.92 (+2.23), TWC: 183.50 (+2.15), HMHC: 25.78 (+0.54), CMCSA: 63.19 (+1.18), UNP: 97.82 (+1.57)
AstraZeneca profit falls as patent expires on heartburn drug
AP - Fri Apr 24, 3:56AM CDT
LONDON (AP) — Anglo-Swedish drug-maker AstraZeneca PLC reported a 7 percent fall in net profit for the first quarter of 2015, as cheaper copies of one of its best-sellers ate into sales.
AZN: 66.45 (+1.90)
Pfizer net down on lower sales, higher research, legal costs
By LINDA A. JOHNSON - AP - Tue Jan 27, 12:43PM CST
Pfizer Inc.'s fourth-quarter profit fell by half as worsening generic competition and unfavorable currency rates reduced sales, and higher research and legal costs also reduced the bottom line.
AZN: 66.45 (+1.90), PFE: 34.36 (+0.50)
Pension charge, lower sales slash Bristol-Myers' Q4 profit
By LINDA A. JOHNSON - AP - Tue Jan 27, 6:58AM CST
NEW YORK (AP) — Bristol-Myers Squibb Co. barely broke even in the fourth quarter, due to a whopping pension charge and slightly lower prescription drug sales, but the drugmaker easily beat Wall Street's muted profit expectations.
AZN: 66.45 (+1.90), BMY: 69.27 (+1.38)
One dose, then surgery: A new way to test brain tumor drugs
By MARILYNN MARCHIONE - AP - Fri Jan 23, 12:57AM CST
Lori Simons took the bright orange pill at 3 a.m. Eight hours later, doctors sliced into her brain, looking for signs that the drug was working.
AZN: 66.45 (+1.90)
AstraZeneca cancer drug, companion test approved
By LINDA A. JOHNSON - AP - Fri Dec 19, 1:39PM CST
TRENTON, N.J. (AP) — U.S. regulators on Friday granted accelerated approval to the first in a new class of targeted drugs for ovarian cancer, Lynparza from British drugmaker AstraZeneca PLC.
MYGN: 34.32 (+0.82), AZN: 66.45 (+1.90)
FDA OKs new AstraZeneca diabetes combo pill
AP - Thu Oct 30, 10:05AM CDT
WILMINGTON, Del. (AP) — AstraZeneca said Thursday it received U.S. approval for a new diabetes medication that combines its drug Farxiga with an older drug used to control blood sugar levels.
AZN: 66.45 (+1.90)
Nektar says FDA clears constipation drug Movantik
AP - Tue Sep 16, 1:02PM CDT
NEW YORK (AP) — Nektar Therapeutics said Tuesday that U.S. regulators approved its drug Movantik, a once-per-day treatment for constipation caused by opioid painkillers.
AZN: 66.45 (+1.90)
Merck 2Q profit more than doubles
By LINDA A. JOHNSON - AP - Tue Jul 29, 10:45AM CDT
A big one-time gain and a tax benefit helped drugmaker Merck & Co. more than double second-quarter profit, improve its profit forecast and top analysts' expectations.
SHPG: 250.34 (+7.35), AZN: 66.45 (+1.90), MRK: 57.95 (+0.57), ABBV: 69.23 (+1.26)
Bristol 2Q net drops on lower drug sales, charges
AP - Thu Jul 24, 9:53AM CDT
NEW YORK (AP) — Bristol-Myers Squibb Co.'s exit from the diabetes business, plus higher taxes and research spending, combined to slash the drugmaker's second-quarter profit by 38 percent, but the company handily beat Wall Street's muted profit expectations.
PFE: 34.36 (+0.50), AZN: 66.45 (+1.90), BMY: 69.27 (+1.38)
